Year in Review 2024 - Ovarian Cancer

Oncology 2024 Year in Review

E. Crane

ASCO® 2024 Summary: "Gynecologic Oncology Updates"

2024 ASCO® Annual Meeting Insights Hub

R. Salani

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

ESMO 2024 Insights: Final OS With Niraparib as 1L Maintenance in Adv…

2024 ESMO Annual Meeting Insights Hub

B. Monk

IGCS 2024 Summary and Highlights: Key Trial Insights on Endometrial …

UCLA Health

D. Chase

Phase 3 ROSELLA Trial Press Release: Primary Endpoint Met As Relacor…

Bradley J. Monk

Comprehensive Review of PARP Inhibitors in Ovarian Cancer: Role of O…

Alexander Olawaiye

SOCCER-P Trial: Secondary Cytoreductive Surgery in Relapsed Ovarian …

Hyun-Woong Cho

Gynecologic Oncology Updates: Expert Perspective on Key Trial Findin…

Yale Cancer Center

E. Ratner

2024 Updates in Clinical Practice for Ovarian Cancer

OncoAlert

I. Ray-Coquard

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

ASCO® 2024 Summary: "Gynecological Cancers Highlights"

2024 ASCO® Annual Meeting Insights Hub

M. Raza Mirza

OVATION 2 Trial: IMNN-001 Immunotherapy + Chemo for Advanced Ovarian…

Premal Thaker

1L Maintenance Therapy in Patients With Newly Diagnosed Advanced Ova…

Bradley J. Monk

ESGO 2025 Summary: HIPEC After Neoadjuvant Chemo - Selecting the Rig…

ESGO & SGO 2025 Annual Meeting Insights

P. De Iaco

Impact of Frontline PARP Inhibitor Approvals on Treatment Decisions …

Erin Crane

Genetic Testing in Determining Maintenance Treatment Options in Adva…

Alexander Olawaiye

ESMO 2024 Insights: Rucaparib +/- Nivo as Maintenance in Newly Diagn…

2024 ESMO Annual Meeting Insights Hub

B. Monk

Next-Generation Immunotherapy for Ovarian Cancer

Ovarian Cancer Midwest Focus, University of Minnesota

S. Powell

SGO 2025 Insights: Luveltamab Tazevibulin in Recurrent Platinum-Resi…

ESGO & SGO 2025 Annual Meeting Insights

B. Monk